Samsung Biologics America Acquires Human Genome Sciences
On December 21, Samsung Biologics announced that its portfolio company, Samsung Biologics America (SBA), will acquire a 100% stake in Human Genome Sciences from GSK. Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, the purchase price is $280 million. Human Genome Sciences operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. Samsung Biologics is a leading contract development and manufacturing organization, offering end-to-end integrated services that range from late discovery to commercial manufacturing. SBA is Samsung... Read More »
Azurity Pharmaceuticals Acquires Sebela Assets
Azurity Pharmaceuticals, a portfolio company of QHP Capital, announced that it acquired select assets from Sebela Pharmaceuticals. The transaction includes two leading bowel preparation therapies for colonoscopies. Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in gastroenterology and a focus on innovation in women’s health. Founded in 1998, Azurity Pharmaceuticals focuses on the needs of special patient populations, such as children and the elderly, for whom customized doses and user-friendly formulations tailored to their needs do not exist. It is based in Woburn, Massachusetts. By integrating Sebela’s bowel prep franchise,... Read More »
Axsome Therapeutics Acquires Baergic Bio
Axsome Therapeutics reported on November 5 that it acquired Baergic Bio, Inc. from Avenue Therapeutics for $0.3 million. Founded in December 2019, Baergic Bio is a clinical-stage pharmaceutical company that focuses on the development of a pharmaceutical product for the treatment of CNS disorders. Axsome Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders. According to its financial reports, the company reported $385.7 million in revenue for the full year 2024. Avenue Therapeutics, a specialty pharmaceutical company, initially purchased Baergic Bio in 2022. The transaction... Read More »
Advent International Sells Zentiva to GTCR
Advent International, a private equity firm focused on buyouts of companies, announced on September 11 that it sold Zentiva to GTCR. Zentiva is a leading European generics pharmaceutical company with a focus on developing, producing and delivering affordable medicines to more than 100 million people in more than 30 countries across Europe and beyond. Zentiva has four wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Founded in 1980, GTCR is a private equity firm focused on investing in growth companies in the business and consumer services, financial services and technology, healthcare and technology and media and... Read More »
CapVest To Buy Majority Stake In STADA
CapVest Partners has signed an agreement with Bain Capital and Cinven to acquire a majority stake in STADA Arzneimittel AG. STADA Arzneimittel manufactures and distributes specialty pharmaceuticals and non-prescription consumer health products. Located in Bad Vilbel, Germany, STADA has evolved from a traditional generics business into a diversified global healthcare platform since its acquisition by Bain Capital and Cinven in 2017. CapVest Partners is an established European mid-market private equity firm focused on acquiring market leading companies supplying essential products and services. CapVest was formed in 1999 and is based in London. The lead financial advisors to CapVest were... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
